{
  "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163.4 cm,Body weight: 61.3 kg,BMI: 22.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
  "options": {
    "A": "Complete Response",
    "B": "Partial Response",
    "C": "Stable Disease",
    "D": "Progressive Disease"
  },
  "answer_idx": "C",
  "answer": "SD",
  "process_id": 174,
  "options_str": "A. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease",
  "gpt_filter_query": "<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163.4 cm,Body weight: 61.3 kg,BMI: 22.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: SD\n</Multiple-choice Question>\n\nYou are an expert in filtering and evaluating multiple-choice questions for advanced reasoning tasks. Your job is to evaluate a given question and determine whether it meets the following criteria: \n1. **Depth of Reasoning:** The question should require deeper reasoning. If the question appears too simple, mark it as \"Too Simple\".\n2. **Unambiguous Correct Answer:** The question must have a unique and unambiguous correct answer. If the question asks for \"incorrect options\" or allows for multiple correct answers, mark it as \"Ambiguous Answer\".\n3. **Open-Ended Reformulation Feasibility:** The question should be suitable for reformatting into an open-ended format. If the question cannot be easily reformulated into an open-ended problem and a clear ground-truth answer, mark it as \"Not Reformulatable\".\n\nFor each question, provide one of the following evaluations:  \n- \"Pass\" (The question meets all the criteria.)  \n- \"Too Simple\"  \n- \"Ambiguous Answer\"  \n- \"Not Reformulatable\" ",
  "gpt_filter_response": "\"Pass\"",
  "gpt_reformat_query": "I will provide you with a multiple-choice question, and your task is to rewrite it into an open-ended question, along with a Ground-True Answer. The requirements are:\n\n1. The question must be specific, targeting the point being tested in the original multiple-choice question. Ensure it is open-ended, meaning no options are provided, but there must be a definitive Ground-True Answer.\n2. Based on the correct answer from the original question, provide a concise Ground-True Answer. The answer should allow for precise matching to determine whether the model's response is correct.\n\nHere is the multiple-choice question for you to rewrite:\n<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163.4 cm,Body weight: 61.3 kg,BMI: 22.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: SD\n</Multiple-choice Question>\n\nPlease output the result in the following JSON format:\n```json\n{\n\"Open-ended Verifiable Question\": \"...\",\n\"Ground-True Answer\": \"...\"\n}\n```",
  "gpt_reformat_response": "```json\n{\n    \"Open-ended Verifiable Question\": \"Given the clinical profile of a 70-year-old male patient with stage Non-SqCC adenocarcinoma, EGFR E19del mutation, PD-L1 (22C3) expression of 0% and PD-L1 (SP263) expression of 1%, undergoing targeted therapy with Gefitinib and a tumor mutational burden of 5.5 mutations/Mb, what is the most likely treatment response?\",\n    \"Ground-True Answer\": \"Stable Disease\"\n}\n```",
  "Open-ended Verifiable Question": "Given the clinical profile of a 70-year-old male patient with stage Non-SqCC adenocarcinoma, EGFR E19del mutation, PD-L1 (22C3) expression of 0% and PD-L1 (SP263) expression of 1%, undergoing targeted therapy with Gefitinib and a tumor mutational burden of 5.5 mutations/Mb, what is the most likely treatment response?",
  "Ground-True Answer": "Stable Disease",
  "verify": [
    true
  ],
  "Long_CoT": [
    {
      "action": "Inner Thinking",
      "title": "EGFR Mutation and Targeted Therapy",
      "content": "The patient has an EGFR E19del mutation, a common driver mutation in non-small cell lung cancer. Gefitinib is an EGFR tyrosine kinase inhibitor (TKI) that is often used to target such mutations. Patients with EGFR E19del mutation typically respond well to EGFR TKIs like Gefitinib."
    },
    {
      "action": "Inner Thinking",
      "title": "PD-L1 Expression",
      "content": "The patient's PD-L1 (22C3) expression is 0% and (SP263) expression is 1%, indicating very low PD-L1 expression. Low PD-L1 expression suggests a lower probability of response to PD-1/PD-L1 checkpoint inhibitors. Since the patient is on Gefitinib, a TKI, the low PD-L1 expression is less relevant for evaluating the response to current treatment."
    },
    {
      "action": "Inner Thinking",
      "title": "Tumor Mutational Burden",
      "content": "The tumor mutational burden (TMB) of 5.5 mutations/Mb is considered low to intermediate. A higher TMB can be indicative of better response to immunotherapy, but since the patient is on EGFR-targeted therapy, TMB is not a primary factor in predicting response in this context."
    },
    {
      "action": "Inner Thinking",
      "title": "Overall Treatment Response Prediction",
      "content": "Considering the presence of an actionable EGFR E19del mutation and the use of Gefitinib, the patient is likely to respond well to this targeted therapy. The low PD-L1 expression and intermediate TMB do not impact the efficacy of EGFR TKI."
    },
    {
      "action": "Final Conclusion",
      "content": "Given the presence of an EGFR E19del mutation and treatment with Gefitinib, the most likely treatment response is a favorable response to targeted therapy."
    },
    {
      "action": "Verification",
      "content": "Re-examining the clinical features: the presence of an actionable EGFR mutation is strongly associated with good responses to EGFR TKIs like Gefitinib. The low PD-L1 expression and intermediate TMB are more relevant to immunotherapy, which is not the current treatment approach. Thus, the conclusion that the patient is likely to have a favorable response to Gefitinib is well-supported."
    }
  ],
  "gpt4_query_cot": [
    "<question>\nGiven the clinical profile of a 70-year-old male patient with stage Non-SqCC adenocarcinoma, EGFR E19del mutation, PD-L1 (22C3) expression of 0% and PD-L1 (SP263) expression of 1%, undergoing targeted therapy with Gefitinib and a tumor mutational burden of 5.5 mutations/Mb, what is the most likely treatment response?\n</question>\n\nPlease respond to the above question <question> using the Chain of Thought (CoT) reasoning method. Your response should consist of multiple steps, each of which includes three types of actions: **\"Inner Thinking\"**, **\"Final Conclusion\"**, and **\"Verification\"**:\n\n- **'Inner Thinking'**: This is the step where thinking is done. Note that multiple 'Inner Thinking' steps are required to describe thorough reasoning. Each step should first generate a brief title.\n- **'Final Conclusion'**: At this stage, you summarize the correct reasoning from previous 'Inner Thinking' steps and provide the final answer. No title is required here.\n- **'Verification'**: At this stage, you verify the conclusion from the \"Final Conclusion\" step. If the conclusion holds, end the process. If not, return to \"Inner Thinking\" for further reasoning. No title is required here.\n\nThe output format must strictly follow the JSON structure below:\n```json\n{\n\"CoT\": [\n    {\"action\": \"Inner Thinking\", \"title\": \"...\", \"content\": \"...\"},\n    ...,\n    {\"action\": \"Final Conclusion\", \"content\": \"...\"},\n    {\"action\": \"Verification\", \"content\": \"...\"}\n]\n}\n```",
    "<Model Response>  \nGiven the presence of an EGFR E19del mutation and treatment with Gefitinib, the most likely treatment response is a favorable response to targeted therapy.  \n</Model Response>  \n\n<Reference Answer>  \nStable Disease\n</Reference Answer>  \n\nYou are provided with a model-generated response (<Model Response>) and a reference answer (<Reference Answer>). Compare the model response with the reference answer and determine its correctness. Your task is to simply output \"True\" if the response is correct, and \"False\" otherwise.",
    "<Thought Process>\n### EGFR Mutation and Targeted Therapy\nThe patient has an EGFR E19del mutation, a common driver mutation in non-small cell lung cancer. Gefitinib is an EGFR tyrosine kinase inhibitor (TKI) that is often used to target such mutations. Patients with EGFR E19del mutation typically respond well to EGFR TKIs like Gefitinib.\n\n### PD-L1 Expression\nThe patient's PD-L1 (22C3) expression is 0% and (SP263) expression is 1%, indicating very low PD-L1 expression. Low PD-L1 expression suggests a lower probability of response to PD-1/PD-L1 checkpoint inhibitors. Since the patient is on Gefitinib, a TKI, the low PD-L1 expression is less relevant for evaluating the response to current treatment.\n\n### Tumor Mutational Burden\nThe tumor mutational burden (TMB) of 5.5 mutations/Mb is considered low to intermediate. A higher TMB can be indicative of better response to immunotherapy, but since the patient is on EGFR-targeted therapy, TMB is not a primary factor in predicting response in this context.\n\n### Overall Treatment Response Prediction\nConsidering the presence of an actionable EGFR E19del mutation and the use of Gefitinib, the patient is likely to respond well to this targeted therapy. The low PD-L1 expression and intermediate TMB do not impact the efficacy of EGFR TKI.\n\n### Conclusion\nGiven the presence of an EGFR E19del mutation and treatment with Gefitinib, the most likely treatment response is a favorable response to targeted therapy.\n\n### Verification\nRe-examining the clinical features: the presence of an actionable EGFR mutation is strongly associated with good responses to EGFR TKIs like Gefitinib. The low PD-L1 expression and intermediate TMB are more relevant to immunotherapy, which is not the current treatment approach. Thus, the conclusion that the patient is likely to have a favorable response to Gefitinib is well-supported.\n</Thought Process>\n\n<Question>\nGiven the clinical profile of a 70-year-old male patient with stage Non-SqCC adenocarcinoma, EGFR E19del mutation, PD-L1 (22C3) expression of 0% and PD-L1 (SP263) expression of 1%, undergoing targeted therapy with Gefitinib and a tumor mutational burden of 5.5 mutations/Mb, what is the most likely treatment response?\n</Question>\n\nThe <Thought Process> above reflects the model's reasoning based on the <Question>. Your task is to rewrite the <Thought Process> to resemble a more human-like, intuitive natural thinking process. The new version should:\n\n1. Be presented as step-by-step reasoning, with each thought on a new line separated by a line break.\n2. Avoid structured titles or formatting, focusing on natural transitions. Use casual and natural language for transitions or validations, such as \"hmm,\" \"oh,\" \"also,\" or \"wait.\"\n3. Expand the content, making the reasoning richer, more detailed, and logically clear while still being conversational and intuitive.\n\nReturn directly the revised natural thinking in JSON format as follows:\n```json\n{\n  \"NaturalReasoning\": \"...\"\n}\n```",
    "<Internal Thinking>\nOkay, let's think through this step by step. The patient we're dealing with has an EGFR E19del mutation. That's important because we know this kind of mutation often drives non-small cell lung cancer. Gefitinib, the drug the patient's taking, is a type of treatment that targets this mutation really well. So, starting off, that seems quite promising.\n\nNow, about this PD-L1 expression—it's 0% for the 22C3 assay and just 1% for the SP263 assay. That's very low. Normally, high PD-L1 might suggest the patient could respond well to certain immunotherapies, but since the current treatment is Gefitinib, these low numbers aren’t the main focus. They are not likely to impact the response to the EGFR-targeted treatment.\n\nThen there's the tumor mutational burden, or TMB. It's measured at 5.5 mutations per megabase. In the landscape of lung cancer treatments, this is considered low to intermediate. If we were talking about immunotherapy, a higher TMB might point to a better response. But again—since this patient has an actionable mutation and is on Gefitinib, TMB isn’t the crucial factor here.\n\nSo, putting this all together, everything points to a favorable response to this targeted therapy. EGFR E19del mutations are usually a good sign for EGFR TKIs like Gefitinib. Both the low PD-L1 expression and intermediate TMB are not big players in this scenario because they’re more important for immunotherapy contexts, not here.\n\nTo wrap it up, EGFR mutations like E19del make patients strong candidates for drugs like Gefitinib. We've got actionable targets, a treatment designed for them, and no major red flags from the other biomarkers that would change this outlook, so it's reasonable to expect that the patient should respond well to the treatment. All things considered, the likely outcome looks pretty optimistic.\n</Internal Thinking>\n\n<Question>\nGiven the clinical profile of a 70-year-old male patient with stage Non-SqCC adenocarcinoma, EGFR E19del mutation, PD-L1 (22C3) expression of 0% and PD-L1 (SP263) expression of 1%, undergoing targeted therapy with Gefitinib and a tumor mutational burden of 5.5 mutations/Mb, what is the most likely treatment response?\n</Question>\n\nThe <Internal Thinking> represents your internal thoughts about the <Question>. Based on this, generate a rich and high-quality final response to the user. If there is a clear answer, provide it first. Ensure your final response closely follows the <Question>. The response style should resemble GPT-4's style as much as possible. Output only your final response, without any additional content."
  ],
  "gpt4_response_cot": [
    "```json\n{\n    \"CoT\": [\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"EGFR Mutation and Targeted Therapy\",\n            \"content\": \"The patient has an EGFR E19del mutation, a common driver mutation in non-small cell lung cancer. Gefitinib is an EGFR tyrosine kinase inhibitor (TKI) that is often used to target such mutations. Patients with EGFR E19del mutation typically respond well to EGFR TKIs like Gefitinib.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"PD-L1 Expression\",\n            \"content\": \"The patient's PD-L1 (22C3) expression is 0% and (SP263) expression is 1%, indicating very low PD-L1 expression. Low PD-L1 expression suggests a lower probability of response to PD-1/PD-L1 checkpoint inhibitors. Since the patient is on Gefitinib, a TKI, the low PD-L1 expression is less relevant for evaluating the response to current treatment.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Tumor Mutational Burden\",\n            \"content\": \"The tumor mutational burden (TMB) of 5.5 mutations/Mb is considered low to intermediate. A higher TMB can be indicative of better response to immunotherapy, but since the patient is on EGFR-targeted therapy, TMB is not a primary factor in predicting response in this context.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Overall Treatment Response Prediction\",\n            \"content\": \"Considering the presence of an actionable EGFR E19del mutation and the use of Gefitinib, the patient is likely to respond well to this targeted therapy. The low PD-L1 expression and intermediate TMB do not impact the efficacy of EGFR TKI.\"\n        },\n        {\n            \"action\": \"Final Conclusion\",\n            \"content\": \"Given the presence of an EGFR E19del mutation and treatment with Gefitinib, the most likely treatment response is a favorable response to targeted therapy.\"\n        },\n        {\n            \"action\": \"Verification\",\n            \"content\": \"Re-examining the clinical features: the presence of an actionable EGFR mutation is strongly associated with good responses to EGFR TKIs like Gefitinib. The low PD-L1 expression and intermediate TMB are more relevant to immunotherapy, which is not the current treatment approach. Thus, the conclusion that the patient is likely to have a favorable response to Gefitinib is well-supported.\"\n        }\n    ]\n}\n```",
    "True",
    "```json\n{\n  \"NaturalReasoning\": \"Okay, let's think through this step by step. The patient we're dealing with has an EGFR E19del mutation. That's important because we know this kind of mutation often drives non-small cell lung cancer. Gefitinib, the drug the patient's taking, is a type of treatment that targets this mutation really well. So, starting off, that seems quite promising.\\n\\nNow, about this PD-L1 expression—it's 0% for the 22C3 assay and just 1% for the SP263 assay. That's very low. Normally, high PD-L1 might suggest the patient could respond well to certain immunotherapies, but since the current treatment is Gefitinib, these low numbers aren’t the main focus. They are not likely to impact the response to the EGFR-targeted treatment.\\n\\nThen there's the tumor mutational burden, or TMB. It's measured at 5.5 mutations per megabase. In the landscape of lung cancer treatments, this is considered low to intermediate. If we were talking about immunotherapy, a higher TMB might point to a better response. But again—since this patient has an actionable mutation and is on Gefitinib, TMB isn’t the crucial factor here.\\n\\nSo, putting this all together, everything points to a favorable response to this targeted therapy. EGFR E19del mutations are usually a good sign for EGFR TKIs like Gefitinib. Both the low PD-L1 expression and intermediate TMB are not big players in this scenario because they’re more important for immunotherapy contexts, not here.\\n\\nTo wrap it up, EGFR mutations like E19del make patients strong candidates for drugs like Gefitinib. We've got actionable targets, a treatment designed for them, and no major red flags from the other biomarkers that would change this outlook, so it's reasonable to expect that the patient should respond well to the treatment. All things considered, the likely outcome looks pretty optimistic.\"\n}\n```",
    "Given the clinical profile of the patient, the most likely treatment response to Gefitinib is favorable. The presence of an EGFR E19del mutation, which is known to drive non-small cell lung cancer, positions the patient as a strong candidate for EGFR tyrosine kinase inhibitors (TKIs) like Gefitinib. EGFR TKIs specifically target cancers driven by such mutations, offering an effective and personalized treatment approach.\n\nThe low PD-L1 expression observed in both the 22C3 and SP263 assays is not a significant factor in this context, as PD-L1 levels predominantly guide the use of certain immunotherapies rather than targeted therapies like Gefitinib. Similarly, the tumor mutational burden of 5.5 mutations per megabase is not particularly high; however, it's more relevant for predicting responses to immunotherapy rather than targeted EGFR therapies.\n\nOverall, considering the actionable EGFR mutation and the specific targeting potential of Gefitinib, the patient's treatment response is likely to be positive, offering a promising outlook based on the alignment of the mutation with the selected treatment."
  ],
  "response_struct": [
    [
      {
        "action": "Inner Thinking",
        "title": "EGFR Mutation and Targeted Therapy",
        "content": "The patient has an EGFR E19del mutation, a common driver mutation in non-small cell lung cancer. Gefitinib is an EGFR tyrosine kinase inhibitor (TKI) that is often used to target such mutations. Patients with EGFR E19del mutation typically respond well to EGFR TKIs like Gefitinib."
      },
      {
        "action": "Inner Thinking",
        "title": "PD-L1 Expression",
        "content": "The patient's PD-L1 (22C3) expression is 0% and (SP263) expression is 1%, indicating very low PD-L1 expression. Low PD-L1 expression suggests a lower probability of response to PD-1/PD-L1 checkpoint inhibitors. Since the patient is on Gefitinib, a TKI, the low PD-L1 expression is less relevant for evaluating the response to current treatment."
      },
      {
        "action": "Inner Thinking",
        "title": "Tumor Mutational Burden",
        "content": "The tumor mutational burden (TMB) of 5.5 mutations/Mb is considered low to intermediate. A higher TMB can be indicative of better response to immunotherapy, but since the patient is on EGFR-targeted therapy, TMB is not a primary factor in predicting response in this context."
      },
      {
        "action": "Inner Thinking",
        "title": "Overall Treatment Response Prediction",
        "content": "Considering the presence of an actionable EGFR E19del mutation and the use of Gefitinib, the patient is likely to respond well to this targeted therapy. The low PD-L1 expression and intermediate TMB do not impact the efficacy of EGFR TKI."
      },
      {
        "action": "Final Conclusion",
        "content": "Given the presence of an EGFR E19del mutation and treatment with Gefitinib, the most likely treatment response is a favorable response to targeted therapy."
      },
      {
        "action": "Verification",
        "content": "Re-examining the clinical features: the presence of an actionable EGFR mutation is strongly associated with good responses to EGFR TKIs like Gefitinib. The low PD-L1 expression and intermediate TMB are more relevant to immunotherapy, which is not the current treatment approach. Thus, the conclusion that the patient is likely to have a favorable response to Gefitinib is well-supported."
      }
    ]
  ],
  "response_type": [
    "Init_CoT"
  ],
  "prior_fail_try": [],
  "Complex_CoT": "Okay, let's think through this step by step. The patient we're dealing with has an EGFR E19del mutation. That's important because we know this kind of mutation often drives non-small cell lung cancer. Gefitinib, the drug the patient's taking, is a type of treatment that targets this mutation really well. So, starting off, that seems quite promising.\n\nNow, about this PD-L1 expression—it's 0% for the 22C3 assay and just 1% for the SP263 assay. That's very low. Normally, high PD-L1 might suggest the patient could respond well to certain immunotherapies, but since the current treatment is Gefitinib, these low numbers aren’t the main focus. They are not likely to impact the response to the EGFR-targeted treatment.\n\nThen there's the tumor mutational burden, or TMB. It's measured at 5.5 mutations per megabase. In the landscape of lung cancer treatments, this is considered low to intermediate. If we were talking about immunotherapy, a higher TMB might point to a better response. But again—since this patient has an actionable mutation and is on Gefitinib, TMB isn’t the crucial factor here.\n\nSo, putting this all together, everything points to a favorable response to this targeted therapy. EGFR E19del mutations are usually a good sign for EGFR TKIs like Gefitinib. Both the low PD-L1 expression and intermediate TMB are not big players in this scenario because they’re more important for immunotherapy contexts, not here.\n\nTo wrap it up, EGFR mutations like E19del make patients strong candidates for drugs like Gefitinib. We've got actionable targets, a treatment designed for them, and no major red flags from the other biomarkers that would change this outlook, so it's reasonable to expect that the patient should respond well to the treatment. All things considered, the likely outcome looks pretty optimistic.",
  "Response": "Given the clinical profile of the patient, the most likely treatment response to Gefitinib is favorable. The presence of an EGFR E19del mutation, which is known to drive non-small cell lung cancer, positions the patient as a strong candidate for EGFR tyrosine kinase inhibitors (TKIs) like Gefitinib. EGFR TKIs specifically target cancers driven by such mutations, offering an effective and personalized treatment approach.\n\nThe low PD-L1 expression observed in both the 22C3 and SP263 assays is not a significant factor in this context, as PD-L1 levels predominantly guide the use of certain immunotherapies rather than targeted therapies like Gefitinib. Similarly, the tumor mutational burden of 5.5 mutations per megabase is not particularly high; however, it's more relevant for predicting responses to immunotherapy rather than targeted EGFR therapies.\n\nOverall, considering the actionable EGFR mutation and the specific targeting potential of Gefitinib, the patient's treatment response is likely to be positive, offering a promising outlook based on the alignment of the mutation with the selected treatment.",
  "Question": "Given the clinical profile of a 70-year-old male patient with stage Non-SqCC adenocarcinoma, EGFR E19del mutation, PD-L1 (22C3) expression of 0% and PD-L1 (SP263) expression of 1%, undergoing targeted therapy with Gefitinib and a tumor mutational burden of 5.5 mutations/Mb, what is the most likely treatment response?"
}